Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.

Bianco A, Reghellin V, Donnici L, Fenu S, Alvarez R, Baruffa C, Peri F, Pagani M, Abrignani S, Neddermann P, De Francesco R.

PLoS Pathog. 2012;8(3):e1002576. doi: 10.1371/journal.ppat.1002576. Epub 2012 Mar 8.

3.

NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.

Reghellin V, Donnici L, Fenu S, Berno V, Calabrese V, Pagani M, Abrignani S, Peri F, De Francesco R, Neddermann P.

Antimicrob Agents Chemother. 2014 Dec;58(12):7128-40. doi: 10.1128/AAC.03293-14. Epub 2014 Sep 15.

4.

The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A.

Reiss S, Harak C, Romero-Brey I, Radujkovic D, Klein R, Ruggieri A, Rebhan I, Bartenschlager R, Lohmann V.

PLoS Pathog. 2013 May;9(5):e1003359. doi: 10.1371/journal.ppat.1003359. Epub 2013 May 9.

5.

Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents.

Leivers AL, Tallant M, Shotwell JB, Dickerson S, Leivers MR, McDonald OB, Gobel J, Creech KL, Strum SL, Mathis A, Rogers S, Moore CB, Botyanszki J.

J Med Chem. 2014 Mar 13;57(5):2091-106. doi: 10.1021/jm400781h. Epub 2013 Aug 14.

PMID:
23944386
6.

Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation.

Lim YS, Hwang SB.

J Biol Chem. 2011 Apr 1;286(13):11290-8. doi: 10.1074/jbc.M110.194472. Epub 2011 Feb 5.

7.

Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication.

Harak C, Radujkovic D, Taveneau C, Reiss S, Klein R, Bressanelli S, Lohmann V.

J Virol. 2014 Sep 1;88(17):9909-26. doi: 10.1128/JVI.01063-14. Epub 2014 Jun 11.

8.

Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.

Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher AM, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G.

J Virol. 2012 Nov;86(21):11595-607. doi: 10.1128/JVI.01320-12. Epub 2012 Aug 15.

9.

Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication.

van der Schaar HM, van der Linden L, Lanke KH, Strating JR, Pürstinger G, de Vries E, de Haan CA, Neyts J, van Kuppeveld FJ.

Cell Res. 2012 Nov;22(11):1576-92. doi: 10.1038/cr.2012.129. Epub 2012 Sep 4.

10.

Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.

Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Bühler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R.

Cell Host Microbe. 2011 Jan 20;9(1):32-45. doi: 10.1016/j.chom.2010.12.002.

11.

Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.

Berger C, Romero-Brey I, Radujkovic D, Terreux R, Zayas M, Paul D, Harak C, Hoppe S, Gao M, Penin F, Lohmann V, Bartenschlager R.

Gastroenterology. 2014 Nov;147(5):1094-105.e25. doi: 10.1053/j.gastro.2014.07.019. Epub 2014 Jul 18.

12.

Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking.

Wang H, Perry JW, Lauring AS, Neddermann P, De Francesco R, Tai AW.

Gastroenterology. 2014 May;146(5):1373-85.e1-11. doi: 10.1053/j.gastro.2014.02.002. Epub 2014 Feb 8.

13.

Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.

Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G.

J Virol. 2011 Sep;85(17):8870-83. doi: 10.1128/JVI.00059-11. Epub 2011 Jun 22.

14.

Modulation of hepatitis C virus genome replication by glycosphingolipids and four-phosphate adaptor protein 2.

Khan I, Katikaneni DS, Han Q, Sanchez-Felipe L, Hanada K, Ambrose RL, Mackenzie JM, Konan KV.

J Virol. 2014 Nov;88(21):12276-95. doi: 10.1128/JVI.00970-14. Epub 2014 Aug 13.

15.

Phosphoinositides in the hepatitis C virus life cycle.

Bishé B, Syed G, Siddiqui A.

Viruses. 2012 Oct 19;4(10):2340-58. doi: 10.3390/v4102340. Review.

16.

Hepatitis C virus NS5A hijacks ARFGAP1 to maintain a phosphatidylinositol 4-phosphate-enriched microenvironment.

Li H, Yang X, Yang G, Hong Z, Zhou L, Yin P, Xiao Y, Chen L, Chung RT, Zhang L.

J Virol. 2014 Jun;88(11):5956-66. doi: 10.1128/JVI.03738-13. Epub 2014 Mar 12.

17.

The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication.

Delang L, Paeshuyse J, Neyts J.

Biochem Pharmacol. 2012 Dec 1;84(11):1400-8. doi: 10.1016/j.bcp.2012.07.034. Epub 2012 Aug 8. Review.

PMID:
22885339
18.

The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement.

Tai AW, Salloum S.

PLoS One. 2011;6(10):e26300. doi: 10.1371/journal.pone.0026300. Epub 2011 Oct 12.

19.

Supplemental Content

Support Center